3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Breast Neoplasms
20
Pain, Postoperative
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Neoplasms
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
4
Prostatic Neoplasms
3
Myoma
3
Leiomyoma
3
Head and Neck Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Agnosia
3
Stomatitis
2
Skin Neoplasms
2
Postoperative Hemorrhage
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Hemorrhage
2
Fatigue
2
Colonic Neoplasms
2
Chronic Pain
2
Carcinoma, Hepatocellular
2
Water-Electrolyte Imbalance
1
Vulvodynia
1
Uterine Cervical Neoplasms
1
Interventions
pegylated granulocyte colony-stimulating factor
3
pegfilgrastim
3
Vancomycin
3
Interleukin 1 Receptor Antagonist Protein
2
Filgrastim
2
Ceftazidime
2
Cefepime
2
Amikacin
2
Vaccination
1
Teicoplanin
1
Tazobactam
1
Surveys and Questionnaires
1
Sodium Chloride
1
Positron Emission Tomography Computed Tomography
1
Pneumococcal Vaccines
1
Piperacillin
1
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Meropenem
1
Linezolid
1
Itraconazole
1
Injections
1
Cloxacillin
1
Ciprofloxacin
1
Cilastatin, Imipenem Drug Combination
1
Bevacizumab
1
Anti-Bacterial Agents
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Febrile Neutropenia
×
Sodium Chloride
×
Clear all
NCT01619423
2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2
Completed
186 enrolled
12 charts